On October 31,‍ JPMorgan low‍ered its price target on GSK plc (NYSE:GSK) to 1,440 GBp fro⁠m 1,550 GBp w⁠hile maintaining an ...

A strong performer already, GSK stock is trading up 44% in 2025, yet its stock remains a good bargain. GSK trades for a ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK has announced the repurchase of 167,000 of its own shares as part of its ongoing ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GlaxoSmithKline (GSK) has announced the purchase of 243,000 of its own ordinary shares ...

ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Mark Hartley isn't convinced by ChatGPT’s attempt at picking dividend shares for retirement. But the results were ...

Trevi Therapeutics is developing nalbuphine ER (Haduvio) for chronic cough in IPF and RCC, targeting unmet medical needs.

Paul Summers looks at a selection of FTSE stocks that he thinks could help bring in passive income in preparation for and ...

Learn more about whether Aurinia Pharmaceuticals Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...